Hepatic Function Panel (Liver Panel)
Liver function tests (the liver panel) comprises biometabolic markers and enzymes produced or modified by the liver. These bimolecular markers are then used to evaluate the function of the liver. Liver cells can be damaged during inflammation caused by infections (e.g., viruses), drugs, poisons, alcohol (liver is the organ that clears toxins and metabolizes/modifies drugs), cancer, and some autoimmune diseases. This can result in leakage of these enzymes into the blood that causes elevation of these enzymes and biomarkers such as SGOT, SGPT, Alkaline phosphatase, GGT, and bilirubin.
In contrast, production of albumin and proteins (including some important functional proteins) can be impaired due to liver damage or fibrosis. Fibrosis is healing by connective tissue fibroblasts and can be reversible if early, or non-reversible (scarring, cirrhosis). Fibrosis results in loss of liver function. Most liver diseases develop slowly and usually are manifested initially by mild symptoms. However, some diseases may be more acute such as acute liver infection (e.g., infection with hepatitis A virus) and develop symptoms quickly. It is important that these diseases be detected early. Detection of liver disease early may avoid damage to the liver completely.
Because this profile is comprised of functional enzymes, proteins, and other molecules produced or modified by the liver, results of these analytes might have different implications. For example, some deal with cellular integrity (AST and ALT), and some with conditions linked to the biliary tract (gamma-glutamyl transferase, alkaline phosphatase, and bilirubin). Some deal with decreased function of the liver; for example, decreased protein/albumin synthesis and increased bilirubin (due to the liver not being able to conjugate bilirubin and therefore eliminate it in the bile). The utility of this panel is in the differential diagnosis of liver disorders such as diseases caused by drugs or other agents, versus those caused by infection. The panel is also used to evaluate the extent of liver damage and management of the disease and response to treatment.
This panel comprises these tests:
- Albumin is the most abundant protein in human plasma and is mainly produced in the liver. It plays a role in maintaining the body fluid oncotic pressure. It also plays an important role in transporting many substances (hormones, vitamins, drugs, other substances) throughout the body. Because the concentration of albumin drops with liver damage, kidney disease, malnutrition, inflammation, and shock, this test can be used to evaluate for diagnosis and monitoring of liver and kidney diseases. Disease is generally associated with decreased levels.
- Total Protein is essential for cellular functions. Plasma protein concentration is determined by nutritional state, hepatic function, renal function, hydration, and various disease states. Plasma protein concentration is the primary determinant of colloidal osmotic pressure. Abnormal levels might indicate liver, kidney, and other systemic diseases.
- ALP (alkaline phosphatase) is found in all tissues throughout the body, but is particularly concentrated in liver, bile duct, intestine, kidney, bone, and the placenta. It is synthesized by biliary epithelium and excreted in bile. Increased serum ALP levels provide useful but nonspecific indication of liver or bone disease. ALP levels increase with obstructive hepatobiliary disease. Increased levels are also seen in hepatic and bone metastases.
- ALT (alanine aminotransferase, SGPT) is synthesized by the liver and is used to evaluate for hepatic diseases.
- AST (aspartate aminotransferase, SGOT) is synthesized by the liver and is used for the evaluation of hepatic diseases.
- Bilirubin is a product of hemoglobin metabolism, transported as a complex with serum albumin to the liver. In the liver, bilirubin is conjugated with glucuronic acid for solubilization and subsequent transport through the bile duct and elimination via the digestive tract. Diseases or conditions which result in production of bilirubin faster than the liver can metabolize it cause the levels of unconjugated (indirect) bilirubin to increase in the circulation.
- Gamma-glutamyl transferase (GGT) is an enzyme synthesized in liver and expressed in kidney and pancreas. It is increased in alcohol intake and is an extremely sensitive indicator of liver disease, particularly alcoholic liver disease.
- Lactate Dehydrogenase (LDH) is an enzyme produced in the liver and catalyzes the conversion of lactate and pyruvate in the presence of NAD/NADH. It is widely distributed in body cells and fluids. This is a non-specific marker of tissue damage, especially muscles. It may be elevated with liver disease but also with a number of other conditions.
- Prothrombin Time (PT) is a test of the extrinsic and common coagulation pathways. It is used as a general screening test (along with the aPTT) in the evaluation of bleeding and to monitor oral anticoagulant therapy (warfarin/Coumadin). A prolonged or increased PT can be seen with liver disease, vitamin K deficiency, DIC, coagulation factor inhibitors, and certain coagulation factor deficiencies.
- Activated Partial Thromboplastin Time (aPTT) is a test of the intrinsic and common coagulation pathways. It is used (with the PT) as a screening test to evaluate bleeding and to monitor anticoagulant therapy (mainly heparin). Prolonged aPTT can be seen with liver disease, coagulation factor inhibitors, DIC, and certain coagulation factor deficiencies.
- Screening for liver diseases
- Assessment or evaluation of liver function in patients with history of liver disease
- Diagnosis of liver diseases
- Differential diagnosis of liver diseases
- Diagnosing alcoholic liver disease
- In diagnosis of liver cancer and metastasis
- Diagnosis of bone diseases
- Diagnosis of bone metastasis
- Monitor the treatment of liver and bone metastasis
- To evaluate nutritional status
- Liver disease management and therapy monitoring
- As an aid in diagnosis of cardiac muscle injury especially in acute myocardial infarction
- As an aid in diagnosis of liver injury, such as liver cirrhosis due to drug toxicity and infection (viral hepatitis)
- As an aid in diagnosis of myeloproliferative disorders, leukemias, and lymphomas
- As an aid in diagnosis of anemias, such as hemolytic anemia, megaloblastic anemias
- Diagnosis of bleeding disorders
- Evaluation of blood clotting as a screening test for factor deficiencies
- Monitoring of oral anticoagulant therapy (warfarin/Coumadin)
Increased in:
- Liver diseases such as acute viral or toxic hepatitis
- Chronic or sub-acute hepatitis
- Alcoholic hepatitis
- Cirrhosis
- Biliary tract obstruction
- Liver neoplasm
- Cardiac muscle injury especially in acute myocardial infarction
- Muscle injury and trauma
- Also increased with the use of some drugs such as phenytoin, carbamazepine, barbiturates, acetaminophen, and others that can damage the liver
- Myeloproliferative disorders, leukemias, and lymphomas
- Anemias such as hemolytic anemia, megaloblastic anemias
- Bleeding and clotting disorders
- Oral anticoagulant therapy (warfarin/Coumadin)
- Dehydration, burns, and trauma
- Shock
Decreased in:
- Severe chronic liver disorders that impact synthesis (chronic liver disease, cirrhosis), malnutrition, malabsorption, malignancy
- Albumins are significantly decreased when there is an increased loss of albumin in states such as nephrotic syndrome, burns, trauma, hemorrhage with fluid replacement, fistulas, enteropathy, acute or chronic glomerulonephritis
- Albumin is also slightly decreased in emodilution
| Test | Reference Range |
| Albumin | 3.4–4.7 g/dL (34–47 g/L) |
| Protein, Total | 6.0–8.0 g/dL |
| Alkaline Phosphatase | 38–137 IU/L |
| Bilirubin, Total | 0.0–1.2 mg/dL |
| SGOT (AST) | 0–35 U/L |
| SGPT (ALT) | 0–35 U/L |
| GGT (Male) | 6–45 U/L |
| GGT (Female) | 5–30 U/L |
| LDH | 88–230 U/L |
| PT | 11–15 sec |
Serum (SST), plasma (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Nutr Clin Pract. 2011 Oct;26(5):565-76. PMID: 21947639]
- Clin Nutr. 2001;20:477. [PMID: 11883995]
- J Am Diet Assoc. 2004;104:1258. [PMID: 15281044]
- Addict Behav. 2004;29:1427. [PMID: 15345274]
- Biochem. 1995 Feb;28(1):1-29. [PMID: 7720223]
- Clin Med. 2002 Sep-Oct;2(5):406-9. [PMID: 12448585]
- Clin Gastroenterol Hepatol. 2005;3:852. [PMID: 16234021]
- CMAJ. 2005;172:367. [PMID: 15684121]
- Am Fam Physician. 1992 Mar;45(3):1139-48. [PMID: 1543099]
- Am Fam Physician. 2004;69:299. [PMID: 14765767]
- Clin Lab Med. 2002;22:377. [PMID: 12134466]
- Thromb Haemost. 2002;87:74. [PMID: 11848460]
- J Thromb Haemos.t 2006;4:967. [PMID: 16689743]
- Jacobs DS and DeMott WR. Laboratory Test Handbook. 5th. Hudson, OH. Lexi-Comp, Inc (2001).